Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

We recently published a list of 10 Best Very Cheap Stocks To Buy Right Now. In this article, we are going to take a look at ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

However, Merck’s (NYSE:MRK) animal health business exceeded forecasts, adding ~$1.4B to the topline with 9% Y/Y growth. Adjusted gross margin was 80.8% for the fourth quarter, compared with 77.2 ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $112.46, a high ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

(RTTNews) - Biopharmaceutical company Merck & Co., Inc. (MRK ... the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and CEO.

Rahway, New Jersey-based Merck & Co., Inc ... the company delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products ...

However, Merck’s (NYSE:MRK) animal health business exceeded forecasts ... which is reflected in its stock price,” Nelissen added.

Merck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...